Yorkville Advisors Global’s NeuroSense Therapeutics NRSN Stock Holding History

Yorkville Advisors Global’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.2K	Hold	78,000	–	–	0.07%	34
2026 Q1	$58.9K	Sell	78,000 -22,000	-22%	-$19.6K	0.04%	36
2025 Q4	$76.9K	Buy	+100,000	New	+$105K	0.05%	25
2025 Q3	–	Sell	-60,000	Closed	-$113K	–	36
2025 Q2	$113K	Buy	+60,000	New	+$86.9K	0.03%	17

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Yorkville Advisors Global's NRSN Position: Q2 2026 in Review

Yorkville Advisors Global held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 78,000 shares worth $56.2K. The position accounts for 0.07% of the portfolio, ranked #34.

Yorkville Advisors Global first reported a position in NRSN in Q2 2025 and has held it in 4 quarters since. The position peaked at $113K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Yorkville Advisors Global held 78,000 shares of NeuroSense Therapeutics worth $56.2K as of Q2 2026.
Yorkville Advisors Global left its NeuroSense Therapeutics share count unchanged in Q2 2026.
NeuroSense Therapeutics made up 0.07% of Yorkville Advisors Global's portfolio in Q2 2026, its #34 holding.
Yorkville Advisors Global first reported a position in NeuroSense Therapeutics in Q2 2025 and has held it in 4 quarters since.
Yorkville Advisors Global's NeuroSense Therapeutics position peaked at $113K in Q2 2025.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Yorkville Advisors Global's 13F filing for Q2 2026, filed 6 Aug 2026.